# US 2025/0205205 A1 · Methods and compositions for preventing and treating fibrosis and improving functional recovery after injury or with aging

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205205 A1
- Document ID: US20250205205A1
- Status: Published application
- Kind: A1
- Application number: 18/844,290
- Filed: 2023-04-12
- Published: 2025-06-26
- Earliest claimed: 2022-04-12
- Assignees: East Carolina University
- Applicants: East Carolina University
- Inventors: Stefan Clemens; Kori Brewer; Mandee Kate Schaub
- Web page: https://patentgrep.com/patent/US20250205205A1

## CPC

- A61K 31/428: condensed with carbocyclic rings
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present inventive concept provides methods for reducing, treating and/or managing inflammation across a wide range of states associated with injury, disease, and/or aging; reducing or inhibiting disease progression and fibrosis, and for improving functional recovery including improvements and/or maintenance in nerve function, recovery, and damage wherein diseases and/or disorders associated with injury to nerve signaling can be completely or partially restored or stabilized. The inventive concept further provides compositions and kits for use in the methods described herein.

## Claims

### Claim 1

A method of reducing, treating, and/or managing fibrosis associated with disease or aging, reducing or inhibiting disease progression and inflammation, and/or for improving functional recovery comprising administering to the subject an effective amount of an opioid and a dopamine type 3 receptor (D3R) agonist, or an effective amount of an opioid and a dopamine type 1 receptor (D1R) antagonist.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method comprises administering an opioid and a dopamine type 3 receptor (D3R) agonist.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method comprises administering an opioid and a dopamine type 1 receptor (D1R) antagonist.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the opioid, and the D3R agonist or the D1R antagonist are administered in the same composition.

### Claim 5 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the opioid, and the D3R agonist or the D1R antagonist are administered in separate compositions.

### Claim 6 (depends on 5)

The method of claim 5, wherein the opioid, and the D3R agonist or the D1R antagonist are administered by the same route.

### Claim 7 (depends on 5)

The method of claim 5, wherein the opioid, and the D3R agonist or the D1R antagonist are administered by different routes.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the opioid, and the D3R agonist or the D1R antagonist are administered via one or more of oral administration, injection, infusion, patch, and a surgically implanted pump.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, further comprising delivering to the subject an additional therapeutic agent.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the subject is a human.

### Claim 11

A composition comprising:
(a) at least one opioid;
(b) at least one dopamine type 3 receptor agonist or a dopamine type 1 receptor antagonist;
(c) an additional therapeutic agent; and
(d) a pharmaceutically acceptable carrier, excipient or diluent.

### Claim 12

A kit for reducing, treating and/or managing fibrosis associated with disease or aging, reducing or inhibiting disease progression and inflammation, and for improving functional recovery comprising at least one opioid and at least one dopamine type 3 receptor agonist or a dopamine type 1 receptor (D1R) antagonist.

### Claim 13

A method of reducing, treating and/or managing a neurodegenerative disease in a subject, the method comprising:
taking a baseline compound action potential (CAP) measurement;
treating the subject with at least one opioid and at least one dopamine type 3 receptor (D3R) agonist or a dopamine type 1 receptor (D1R) antagonist;
taking an additional baseline compound action potential (CAP) measurement after treating the subject with the at least one opioid and at least one D3R agonist or the D1R antagonist; and
assessing whether the CAP (amplitude, area, conduction velocity, and latency) is stabilized or improves over time.

### Claim 14 (depends on 13)

The method of claim 13, wherein treating and/or managing the neurodegenerative disease comprises treating and/or managing inflammation associated with the neurodegenerative disease.

### Claim 15

A method of reducing, treating, and/or managing inflammation resulting from injury, disease, and/or aging in a subject, the method comprising administering to the subject an effective amount of an opioid and a dopamine type 3 receptor (D3R) agonist, or an effective amount of an opioid and a dopamine type 1 receptor (D1R) antagonist.

### Claim 16 (depends on 15)

The method of claim 15, wherein reducing, treating, and/or managing of inflammation comprises reducing, treating, and/or managing of fibrosis associated with the inflammation.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, wherein the method comprises administering an opioid and a dopamine type 3 receptor (D3R) agonist.

### Claim 18 (depends on 15, 16)

The method of claim 15 or 16, wherein the method comprises administering an opioid and a dopamine type 1 receptor (D1R) antagonist.

### Claim 19 (depends on 15, 16, 17, 18)

The method of any one of claims 15-18, wherein the opioid, and the D3R agonist or the D1R antagonist are administered in the same composition.

### Claim 20 (depends on 15, 16, 17, 18)

The method of any one of claims 15-18, wherein the opioid, and the D3R agonist or the D1R antagonist are administered in separate compositions.

### Claim 21 (depends on 20)

The method of claim 20, wherein the opioid, and the D3R agonist or the D1R antagonist are administered by the same route.

### Claim 22 (depends on 20)

The method of claim 20, wherein the opioid, and the D3R agonist or the D1R antagonist are administered by different routes.

### Claim 23 (depends on 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 15-22, wherein the opioid, and the D3R agonist or the D1R antagonist are administered via one or more of oral administration, injection, patch, and a surgically implanted pump.

### Claim 24 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 15-23, further comprising delivering to the subject at least an additional therapeutic agent.

### Claim 25 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 15-24, wherein the subject is a human.

### Claim 26

A kit for reducing, treating and/or managing inflammation associated with disease or aging, reducing or inhibiting disease progression and/or fibrosis associated with the inflammation, and for improving functional recovery comprising at least one opioid and at least one dopamine type 3 receptor agonist or a dopamine type 1 receptor (D1R) antagonist.

### Claim 27 (depends on 11)

The composition of claim 11 for use in reducing, treating, and/or managing inflammation resulting from injury, disease, and/or aging in a subject.

### Claim 28 (depends on 27)

The composition of claim 27, wherein reducing, treating, and/or managing of inflammation comprises reducing, treating, and/or managing of fibrosis associated with the inflammation.

### Claim 29

Use of an effective amount of an opioid and a dopamine type 3 receptor (D3R) agonist, or an effective amount of an opioid and a dopamine type 1 receptor (D1R) antagonist in the manufacture of a medicament for reducing, treating, and/or managing inflammation resulting from injury, disease, and/or aging in a subject.

### Claim 30 (depends on 29)

The use of claim 29, wherein reducing, treating, and/or managing of inflammation comprises reducing, treating, and/or managing of fibrosis associated with the inflammation.
